Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Primary Myelofibrosis | 6 | 2012 | 7 | 1.440 |
Why?
|
| Polycythemia Vera | 1 | 2012 | 2 | 0.420 |
Why?
|
| Benzodiazepines | 1 | 2011 | 9 | 0.390 |
Why?
|
| Monosomy | 1 | 2011 | 5 | 0.380 |
Why?
|
| Cytokines | 1 | 2012 | 256 | 0.370 |
Why?
|
| Survivors | 1 | 2011 | 163 | 0.350 |
Why?
|
| Anxiety | 1 | 2011 | 191 | 0.350 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2020 | 15 | 0.340 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 201 | 0.320 |
Why?
|
| Survival Rate | 6 | 2018 | 876 | 0.310 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2017 | 22 | 0.280 |
Why?
|
| Disease-Free Survival | 5 | 2018 | 317 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 458 | 0.250 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 765 | 0.240 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 3990 | 0.230 |
Why?
|
| Prognosis | 6 | 2015 | 1496 | 0.220 |
Why?
|
| Karyotyping | 3 | 2011 | 29 | 0.210 |
Why?
|
| Proportional Hazards Models | 4 | 2012 | 753 | 0.200 |
Why?
|
| Adult | 8 | 2018 | 9375 | 0.200 |
Why?
|
| Middle Aged | 9 | 2018 | 11834 | 0.190 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2020 | 6 | 0.180 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2020 | 10 | 0.180 |
Why?
|
| Aged | 8 | 2018 | 10308 | 0.170 |
Why?
|
| Organ Transplantation | 1 | 2020 | 66 | 0.170 |
Why?
|
| Multivariate Analysis | 2 | 2012 | 684 | 0.170 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 11 | 0.160 |
Why?
|
| Immunoglobulins | 1 | 2018 | 14 | 0.160 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2018 | 16 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2018 | 6 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 34 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 28 | 0.160 |
Why?
|
| Female | 9 | 2018 | 20002 | 0.150 |
Why?
|
| Hyperglycemia | 1 | 2017 | 84 | 0.150 |
Why?
|
| Humans | 11 | 2020 | 32086 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2012 | 873 | 0.130 |
Why?
|
| Male | 8 | 2018 | 19206 | 0.120 |
Why?
|
| Cytogenetic Analysis | 2 | 2011 | 17 | 0.120 |
Why?
|
| Phenotype | 2 | 2012 | 632 | 0.110 |
Why?
|
| Etoposide | 3 | 2018 | 34 | 0.110 |
Why?
|
| Vincristine | 3 | 2018 | 17 | 0.110 |
Why?
|
| Cyclophosphamide | 3 | 2018 | 38 | 0.110 |
Why?
|
| Prednisone | 3 | 2018 | 61 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2012 | 895 | 0.110 |
Why?
|
| Doxorubicin | 3 | 2018 | 82 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 367 | 0.110 |
Why?
|
| Medical Records | 1 | 2011 | 76 | 0.100 |
Why?
|
| Interleukin-15 | 1 | 2011 | 4 | 0.100 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2011 | 8 | 0.100 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 15 | 0.090 |
Why?
|
| Interleukin-8 | 1 | 2011 | 26 | 0.090 |
Why?
|
| Platelet Count | 1 | 2010 | 23 | 0.090 |
Why?
|
| Interleukin-12 | 1 | 2011 | 28 | 0.090 |
Why?
|
| Leukemia | 1 | 2010 | 40 | 0.090 |
Why?
|
| Retrospective Studies | 3 | 2018 | 3505 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2010 | 73 | 0.090 |
Why?
|
| Blood Transfusion | 1 | 2010 | 73 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 2263 | 0.090 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 13 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 94 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 560 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2015 | 3305 | 0.070 |
Why?
|
| Adolescent | 3 | 2011 | 3569 | 0.070 |
Why?
|
| Minnesota | 2 | 2011 | 22 | 0.050 |
Why?
|
| Bone Marrow Examination | 2 | 2011 | 8 | 0.050 |
Why?
|
| United States | 1 | 2009 | 3975 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 297 | 0.040 |
Why?
|
| Risk Factors | 3 | 2011 | 3880 | 0.040 |
Why?
|
| Disease Progression | 1 | 2020 | 594 | 0.040 |
Why?
|
| Time Factors | 2 | 2011 | 2145 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 74 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2017 | 494 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2015 | 124 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2011 | 1427 | 0.030 |
Why?
|
| Young Adult | 2 | 2011 | 2665 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2011 | 23 | 0.020 |
Why?
|
| Janus Kinase 2 | 1 | 2011 | 6 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2010 | 22 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2010 | 49 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2010 | 49 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 152 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 57 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 189 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 483 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2011 | 354 | 0.020 |
Why?
|
| Biopsy | 1 | 2011 | 259 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 733 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 486 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 765 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 881 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 1187 | 0.020 |
Why?
|